Copyright
©2014 Baishideng Publishing Group Inc.
World J Gastroenterol. Oct 14, 2014; 20(38): 13741-13755
Published online Oct 14, 2014. doi: 10.3748/wjg.v20.i38.13741
Published online Oct 14, 2014. doi: 10.3748/wjg.v20.i38.13741
Table 5 Clinical trials of everolimus
Patients | Phase | Treatment | n | OS (mo) | PFS (mo) | RR | DCR |
Previously treated metastatic gastric cancer | II | Everolimus | 53 | 10.1 | 2.7 | 0% | 54.7% |
Second-line treatment for advanced gastric cancer (GRANITE-1) | III | Placebo | 217 | 4.34 | 1.41 | 2.1% | N/A |
Everolimus | 439 | 5.39 | 1.68 | 4.5% | N/A |
- Citation: Aoyagi K, Kouhuji K, Kizaki J, Isobe T, Hashimoto K, Shirouzu K. Molecular targeting to treat gastric cancer. World J Gastroenterol 2014; 20(38): 13741-13755
- URL: https://www.wjgnet.com/1007-9327/full/v20/i38/13741.htm
- DOI: https://dx.doi.org/10.3748/wjg.v20.i38.13741